CPT1A and metabolic dysfunction-associated steatotic liver disease: The existing experimental results disclosed that HFD exposure and PA treatment, respectively resulted in the increase in HMGCR, FABP1, and FAS expression and the decrease in CPT1A expression in the liver tissues of NAFLD mice and AML‐12 cells, which were all restored by downregulation of Asprosin.